Exercise Intolerance in Renal Failure (EIRF)

Emory University

Status and phase: Completed; Phase 2

Conditions: Kidney Failure, Chronic

Treatments: Drug: Tetrahydrobiopterin; Dietary Supplement: Folate; Drug: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01356966

K23HL098744 (U.S. NIH Grant/Contract)

IRB00019181

Details and patient eligibility

About

Patients with chronic kidney disease have profound exercise intolerance which contributes to an increased risk of cardiovascular disease. The investigators have found that chronic kidney disease patients have an exaggerated increase in blood pressure during certain forms of exercise that could certainly contribute to exercise dysfunction as well as cardiovascular risk. The investigators will test the mechanisms underlying this exaggerated blood pressure response, as well as the potential benefits of short-term tetrahydrobiopterin (BH4) with folic acid on both exercise dysfunction and cardiovascular risk factors in chronic kidney disease. The investigators will test whether short-term treatment with tetrahydrobiopterin (BH4), a cofactor for nitric oxide, together with folic acid improves inflammation, vascular health, and adrenaline levels, both at rest and during exercise in chronic kidney disease.

Enrollment: 74 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• chronic kidney disease (CKD) stages I, II, and III and do not regularly exercise

  1. CKD Stages I, II, and III will be defined as reduction in estimated glomerular filtration rate (eGFR) to 30-59 cc/minute as calculated by the Modification of Diet in Renal Disease (MDRD) equation, or an eGFR>60 cc/minute with proteinuria greater than 500 mg/g of Creatinine or 500 mg per 24 hours.

• willing and able to cooperate with the protocol

• CKD patients must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months)

• controls will be matched for age, gender, race, and hypertensive status.

Exclusion criteria

• severe CKD (eGFR<30 cc/minute)
• drug or alcohol abuse
• diabetes
• any serious systemic disease that might influence survival
• severe anemia with hgb level <10 g/dL
• clinical evidence of congestive heart failure or ejection fraction below 35%
• any history of past myocardial infarction or cerebrovascular accident
• symptomatic heart disease determined by electrocardiogram, stress test, and/or history
• treatment with central alpha agonists
• uncontrolled hypertension with BP greater than 160/90 mm Hg
• low blood pressure with BP less than 110/60
• history of nephrolithiasis
• pregnancy or plans to become pregnant
• treatment with vitamin C within the past 3 months
• hepatic enzyme concentrations greater than 2 times the upper limit of normal
• HIV infection
• surgery within the past 3 months
• previous treatment with BH4
• known hypersensitivity to BH4
• any condition that places the participant at high risk of poor adherence or poor follow-up
• patients must be willing to use an acceptable method of contraception if of childbearing age

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

74 participants in 2 patient groups, including a placebo group

Tetrahydrobiopterin + Folate

Experimental group

Description:

Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily

Treatment:

Dietary Supplement: Folate

Drug: Tetrahydrobiopterin

Placebo + Folate

Placebo Comparator group

Description:

Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily

Treatment:

Dietary Supplement: Folate

Drug: Placebo